The Max Foundation’s 2019 Annual Report is Now Live

We are pleased to announce the publication of The Max Foundation’s 2019 Annual Report, showcasing the variety of achievements made possible with the support of our dedicated donors, partners, and global team.

Read the 2019 Annual Report

“Looking back at 2019 a common theme stands out: reaching new frontiers,” write The Max Foundation CEO Pat Garcia-Gonzalez and The Max Foundation Board President Paula Boultbee in the report.

These new frontiers include our program’s expansion into Mozambique, where chronic myeloid leukemia (CML) patients gained access to lifesaving treatment for the first time. We also grew our access to diagnostics initiatives that allowed patients to have access to affordable and local molecular tests. And through our patient services, we connected with thousands of patients and their caregivers worldwide through one-on-one support and community outreach.

In this report, we celebrate our organization’s achievements as well as patients’ milestones—each with a unique journey toward accessing treatment and care.

We’re thrilled to share with you the significance of our growth into new frontiers, and the impact it’s had on the patients we support worldwide. We hope you see yourself in each of our achievements and feel how your support directly contributes to the lives of patients and families who are now able to face their cancer with dignity and hope.

Read the 2019 Annual Report

See All News

The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 27 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.

The Max Foundation (Max) Expands Collaboration with Novartis to Include Access to Innovative Treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH)
Max to immediately begin process to provide humanitarian access for Fabhalta® (iptacopan) in collaboration with its network of partner hematologists across 53 countries People living with the rare blood disease in low-middle income countries require frequent blood transfusions, experience debilitating symptoms of fatigue and without treatment may progress to more serious life-threatening diseases The Max….
The Max Foundation (Max) and the International PNH Interest Group (IPIG) Announce Collaboration to Improve Care and Management for People Living with Paroxysmal Nocturnal Hemoglobinuria (PNH) in Low-Resource Countries
IPIG joins Max’s Humanitarian Partnership for Access to Critical Treatments (Humanitarian PACT) and will provide medical education and training on PNH care and management Max will provide access to innovative treatment as part of the multi-stakeholder collaboration focused on eradicating survival disparities in 53 low-resource countries People living with this rare blood disease require frequent….
Acting with humanity – donating my birthday – supporting cancer patients in Nepal
Last October I had the privilege of visiting Patan Hospital in Nepal on behalf of The Max Foundation. Right then, I knew I would dedicate my next birthday to supporting people in need of cancer treatment in the country by covering the cost of diagnostics and transportation, especially for families of children facing a cancer….